Advances in organ preservation, surgical technique, and post operative care
have permitted the rapid development of liver transplantation in children.
Consequently, the applicability of this procedure has gone beyond the trea
tment of life-threatening complications of chronic liver disease and now in
cludes disabling morbidities and quality-of-lifo issues. The use of hepatic
segments for transplantation with reduced or split cadaveric grafts and li
ving-related donors has decreased the mortality of children awaiting liver
transplantation. We are presently armed with a new potent immunosuppressive
drug, tacrolimus, and an understanding that the migration and grafting of
passenger leukocytes of bone marrow origin is the seminal explanation for a
llograft acceptance. The next forefront will involve manipulation of the pr
ocess, not only for the transplantation of already successful whole organs-
such as the liver, kidney, pancreas, and heart-but also in the development
of the intestinal transplantation program. Thus, augmentation of leukocyte
traffic in unconditioned recipients of cadaver allografts with concomitant
intravenous infusion of donor bone marrow cells under the same immunosuppre
ssive management of tacrolimus-prednisone will be the path to the future.